Zentalis Pharmaceuticals, Inc.
ZNTL

$213.8 M
Marketcap
$3.00
Share price
Country
$0.07
Change (1 day)
$18.07
Year High
$2.66
Year Low
Categories

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

marketcap

Revenue of Zentalis Pharmaceuticals, Inc. (ZNTL)

Revenue in 2023 (TTM): $

According to Zentalis Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Zentalis Pharmaceuticals, Inc.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $ $-1,389,000 $-275,503,000 $-276,892,000 $-292,191,000
2022 $ $-1,426,000 $-219,874,000 $-221,300,000 $-220,831,000
2021 $ $-544,000 $-164,015,000 $-164,559,000 $-164,262,000
2020 $ $-160,000 $-117,944,000 $-118,104,000 $-118,548,000
2019 $ $-111,000 $-46,734,000 $-46,363,000 $-46,378,000
2018 $14 K $14 K $-23,732,000 $-23,428,000 $-21,067,000